Transmission of HIV-1 variants with resistance to reverse transcriptase (RT) and protease inhibitors has been widely characterized in developed countries. However, no clear evidence of primary resistance to HIV-1 fusion inhibitors has been shown so far. We wished to investigate the possibility of genotypic resistance to enfuvirtide (T20) in a cohort of antiretroviral-naive, recently infected patients.
Methods
We included patients from the Aquitaine Cohort with an estimated date of seroconversion in 2004 and 2005, a plasma sample obtained less than 18 months after seroconversion and no prior history of antiretroviral therapy. RT, protease and gp41 sequences were determined by direct population sequencing from plasma samples and drug resistance mutations were reported.
Results
A total of 55 patients were included in the study. The overall prevalence of transmitted HIV-1 resistance was 20%. Two patients had viruses with resistance mutations to T20. The first case had an N42D mutation in the HR1 region of the gp41, along with transmitted resistance mutations in the protease (D30N, M36I, N88D) and in the RT (M41L, L210W, T215D). The second case had a G36D HR1 mutation, with no evidence of other drug resistance mutations.
Conclusion
We have shown the first cases of primary resistance to T20 in recently infected patients in southwestern France. Epidemiological surveillance of the transmission of drug-resistant HIV-1 should include the resistance to T20.
References
1.
HirschM.S., Brun-VezinetF., ClotetB.Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.Clin Infect Dis2003; 37: 113–128.
2.
BlowerS.M., AschenbachA.N., GershengornH.B., KahnJ.O.Predicting the unpredictable: transmission of drug-resistant HIV.Nat Med2001, 7: 1016–1020.
3.
LittleS.J., HolteS., RoutyJ.P.Antiretroviral-drug resistance among patients recently infected with HIV.N Engl J Med2002; 347: 385–394.
4.
MasquelierB., BhaskaranK., PillayD.Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.J Acquir Immune Defic Syndr2005; 40: 505–511.
5.
WensingA.M., van de VijverD.A., AngaranoG.Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.J Infect Dis2005; 192: 958–966.
GreenbergM.L., CammackN.Resistance to enfuvirtide, the first HIV fusion inhibitor.J Antimicrob Chemother2004; 54: 333–340.
8.
KilbyJ.M., EronJ.J.Novel therapies based on mechanisms of HIV-1 cell entry.N Engl J Med2003; 348: 2228–2238.
9.
MinkM., MosierS.M., JanumpalliS.Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.J Virol2005; 79: 12447–12454.
10.
BaldwinC.E., SandersR.W., DengY.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.J Virol2004; 78: 12428–12437.
11.
SistaP.R., MelbyT., DavisonD.Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.AIDS2004; 18: 1787–1794.
12.
WeiX., DeckerJ.M., LiuH.Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Antimicrob Agents Chemother2002; 46: 1896–1905.
13.
MelbyT., SistaP., DemasiR.Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.AIDS Res Hum Retroviruses2006; 22: 375–385.
14.
CarmonaR., Perez-AlvarezL., MunozM.Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.J Clin Virol2005; 32: 248–253.
15.
ThiebautR., MorlatP., Jacqmin-GaddaH.Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA).AIDS2000; 14: 971–978.
16.
MenzoS., CastagnaA., MonachettiA.Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.Antimicrob Agents Chemother2004; 48: 3253–3259.
17.
Perez-AlvarezL., CarmonaR., OcampoA.Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.J Med Virol2006; 78: 141–147.
18.
ChinnaduraiR., MunchJ., KirchhoffF.Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.AIDS2005; 19: 1401–1405.
19.
CostagliolaD., Morand-JoubertL., AssoumouL.Prevalence of resistance to at least 1 drug in treated HIV-infected patients with viral load >1000 copies/ml: a French nationwide study.13th Conference on Retroviruses & Opportunistic Infections. 5–9 February 2006, Denver, CO, USA. Abstract 648.
